
BVIKM - SBIMC WORKING GROUPS: ACTIVITIES AND CHALLENGES

FROM IGGI 1.0 TO IGGI 2.0


JAN VANCAUWENBERGHE
Project Manager BVIKM - SBIMC
















- 1987 \rightarrow 2013 (total of 23 editions).
 - 1987 1990: distribution under license by Beecham Pharma.
 - 1987 1990: distribution under license by SmithKline Beecham Pharma.
 - 1991 2000: distribution under license by GlaxoSmithKline.
 - 2008 2013: distribution under license by the BVIKM-SBIMC (2-yearly editions).
- Evolution from 123 pages → 500 pages.
- Mostly based on expert opinion + review of the literature (no GRADE system).
- Maximum print run of 20,000 copies, distributed for free.

- 2013 → 2017.
 - Recognition of the need for an electronic version of the guide.
 - Unsuccessful negotiations with Jeb Sanford to continue the collaboration.
 - Development BVIKM-SBIMC website.
 - Decision to create a new tool in FR and NL.
 - IGGI: InfectiologieGids-Guide d'Infectiologie, embedded in the new website.



Belgische vereniging voor infectiologie en klinische microbiologie



Infectiologiegids - Guide d'infectiologie





Q4 2017: launch of IGGI 1.0.

- Payable institutional and individual licenses.
- Currenty +/- 1,400 PDF files in Dutch and equal N in French.

Belgische vereniging voor infectiologie en klinische microbiologie




• 2017 \rightarrow today.

- Financially healthy situation (financially self-supporting).
- Almost 40% of Belgian hospitals have subscribed and are currently using IGGI.
- > 200,000 times a page of IGGI has been consulted since December 2018.
- Mean of 5,000 hits per month since the measurements started.
- Positive trend: increasing N of hits.











- Evaluation of IGGI (version 1.0) 4 years after its launch shows that there is room for improvement at different levels.
 - Userfriendliness [usability on smaller screens (tablet, smartphones) currently difficult because of pdf form, improved search engine, ...].
 - Difficulties to reach the update objective (100% every 2 years) as a consequence of the difficulties to create, motivate, ... ad hoc working groups [important workload of the members, especially (but not exclusively) in the context of covid-19].
 - Absence of a transparent and consistent methodology for the update of the guidelines.





Decisions taken by the BVIKM-SBIMC board.

- Creation of an IGGI steering committee (SC) composed of infectiologists (including a paediatrician), microbiologists and hospital pharmacists to guide the further development of IGGI 2.0.
- Search for sustained [financial and other (endorsement)] support from partners such as the Belgian government (BAPCOC), the Belgian Association of Hospital Pharmacists, scientific societies, Sciensano, KCE, ...
- Recruitment of a scientific collaborator for the management of the scientific aspects of IGGI 2.0.
- Replacement of the current version by an updated version IGGI 2.0.



Belgische vereniging voor infectiologie en klinische microbiologie



IGGI 2.0 Steering Committee responsibilities.

- Working group that will manage the conversion of IGGI 1.0 to IGGI 2.0 and the further development of IGGI (reporting to the board of the BVIKM-SBIMC).
 - To recruit a scientific collaborator (1/2 FTE).
 - To prioritise the IGGI chapters for review.
 - To clean up the overall contents of the current version 1.0 (references).
 - To guide the transition to the new electronic format.
 - To solve generic issues which may have an impact throughout the whole guide (consistency).
 - To compose the working groups that will review the selected chapters (volunteers for these working groups are more than welcome).

■





IGGI 2.0 Steering Committee.

- First meeting January 27 2022, since then regular monthly meetings.
- Members.
 - BRIQUET Caroline, hospital pharmacist (Clin. Univ. Saint-Luc Bruxelles).
 - DELAERE Bénédicte, infectiologist (Clin. Univ. Saint-Luc Namur).
 - DE GEYTER Deborah, microbiologist (UZ Brussel).
 - DE SCHEPPER Lotte, hospital pharmacist (UZ Gent).
 - NEBBIOSO Andrea, paediatrician (Hôpital d'Ixelles, Bruxelles).
 - PIERARD Denis, microbiologist (UZ Brussel).
 - TEN KATE Luit, infectiologist (UZ Antwerpen).




IGGI 2.0 Scientific Collaborator.

- Recruitment ongoing (almost finalised).
- Job description.
 - Development of a transparent and consistent methodology for the review.
 - Scientific transition to the new format.
 - Set-up and preparation (literature study, EBM) of working parties, communication with experts, follow-up timelines.
 - Organisation of working meetings.
 - Update of existing and writing of new guidelines, in collaboration with experts in the field (working groups).
 - **.** . . .



IGGI 2.0 Coordinator.

- Job description: management of all non-scientific aspects of IGGI 2.0.
 - Practical organisation of the transition to the new format in collaboration with the Dutch provider IDMC (Infectious Diseases Management Corporation) / IDM Alert).
 - Translation of the existing IGGI 1.0 documents in English.
 - Accountancy, financial management of IGGI 2.0 (funding excluded).
 - Follow-up of all practical issues related to IGGI 2.0 (licenses, invoices, ...).
 - Management of the BVIKM-SBIMC website (IGGI 2.0 embedded).
 - **...**



Nationale AntibioticaBoekje van de SWAB

Welkom bij het Nationale AntibioticaBoekje van de SWAB!

De SWAB, de Stichting Werkgroep AntibioticaBeleid, heeft een nationaal antibiotica boekje samengesteld, waarin adviezen worden gegeven voor therapie en profylaxe van de gangbare infectieuze ziektebeelden, en waarin ook de belangrijkste eigenschappen van alle antimicrobiële middelen te vinden zijn.

De ziektebeelden zijn in principe gerangschikt op 'orgaansysteem'. Voor die gevallen waar dit niet het gezochte ziektebeeld oplevert, biedt de 'zoek' knop meestal wel uitkomst.































Advices

≥ 18 years

Indications: Patients without arthritis or osteomyelitis in the infected foot and without risk factors for infections due to MRSA, No IgE mediated allergy to penicillins

Priority	Medication	Remarks
1st choice	Amoxicilline + clavulanate iv 2g q8h + Amoxicilline + clavulanate iv 200mg q8h	Can be used in pregnant patients (see footnote 3). Can be used during breastfeeding (see footnote 3).
1st choice	Amoxicilline + clavulanate iv 1g + Amoxicilline + clavulanate iv 200mg q6h	Can be used in pregnant patients (see footnote 3). Can be used during breastfeeding (see footnote 3).

- Clindamycin
- Ciprofloxacin
- Levofloxacin
- Moxifloxacin
- Vancomycin
- Meropenem

Menu position

Skin and soft tissue

Metadata






































- IGGI 2.0 version: phase I.
 - o Asap.
 - Elaboration of the methodology for in depth reviews.
 - Prioritisation of chapters for in depth review.
 - Identification of urgently needed new chapters.
 - Sanitation of the other chapters.
 - New version available 1 year after the start of the activities of the scientific collaborator (July 1st 2023).
 - Complete in depth review every 5 years.
 - Abrupt switch form IGGI 1.0 to IGGI 2.0 (preferable) versus period of overlap?





IGGI 2.0 version: phase II.

- Creation of the possibility to easily adapt the IGGI 2.0 contents to local needs:
 → set of guidelines per hospital (group) as is the case in the Netherlands (tool exists).
- Structural (sustained) financial support mandatory.

Belgische vereniging voor infectiologie en klinische microbiologie



IGGI 2.0 version: prioritisation.

- Urinary tract infections: empirical treatment.
- Osteo-articular infections: empirical treatment.
- Dosing of anti-infectives in patients with renal impairment.
- Vaccination.
- Treatment of infections due to non-tuberculous mycobacteria (MOTT).
- 0 ...

Belgische vereniging voor infectiologie en klinische microbiologie



Quid with IGGI 1.0 in the meantime?

- Adaption to new EUCAST directives (S | R).
- Correction of (major) errors.
- Adaptation in case of major changes.
 - Availability of new drugs on the Belgian market.
 - Disappearance of currently available anti-infective drugs.
 - Publication of new (inter)national recommendations/guidelines.
 - ...





